How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,313 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

Rosuvastatin LDH Lactate dehydrogenase LDL-C LDL cholesterol LEAD Lower extremity artery disease LIFE Losartan Intervention For Endpoint reduction in hypertension LV Left ventricular LVH Left ventricular hypertrophy MAP Mean arterial pressure MI Myocardial infarction MR Magnetic resonance MRA Mineralocorticoid receptor antagonist MRI Magnetic resonance imaging MUCH Masked uncontrolled hypertension NORDIL Nordic Diltiazem NS Non-significant NT-proBNP N-terminal pro-B natriuretic peptide o.d. Omni die (every (...) million), and ischaemic stroke (1.5 million). Both office BP and out-of-office BP have an independent and continuous relationship with the incidence of several CV events [haemorrhagic stroke, ischaemic stroke, myocardial infarction, sudden death, heart failure, and peripheral artery disease (PAD)], as well as end-stage renal disease. Accumulating evidence is closely linking hypertension with an increased risk of developing atrial fibrillation (AF), and evidence is emerging that links early elevations

2018 European Society of Cardiology

283. Sodium zirconium cyclosilicate (Lokelma) - Hyperkalemia

are usually between 3.5 and 5.0 mmol/L, which is considered the normal range for adults. However, a number of recent retrospective studies have shown the risk of mortality is increased even with only modest elevations of S-K. Mortality risk has been shown to be significantly higher in chronic kidney disease (CKD) patients with S-K levels > 5.0 mmol/L. In acute myocardial infarction patients, a mean postadmission S-K = 5.5 mmol/L during hospitalisation corresponded to a 12-fold increase in death compared (...) of the active substance are provided. The results are within the specifications and consistent from batch to batch. The active substance specifications are based on the active substance critical quality attributes (CQA). Stability Stability data on six commercial scale batches of the active substance from the proposed manufacturer stored in a container closure system representative of that intended for commercial production were provided. Data on three batches was provided for 24 months under long term

2018 European Medicines Agency - EPARs

284. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

through extensive form screening experiments and crystallization studies and is the only form of ertugliflozin L-PGA. All batches of ertugliflozin L-PGA have been consistent. In addition, confirmation of form has been evaluated as part of the supportive and primary stability programs (36 months & 12 months at 25 °C/60% RH; respectively) using powder x-ray diffraction (PXRD) with no changes being observed. Ertugliflozin L-PGA is a white to off-white powder. Ertugliflozin is very slightly soluble (...) testing has been presented. Batch analysis data from full scale batchesof the active substance are provided. The results are within the specifications and consistent from batch to batch. Stability Stability data from full scale batches of active substance from the proposed manufacturer, stored in the intended commercial package for up to 12 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were

2018 European Medicines Agency - EPARs

285. Reducing Acute Care Length of Stay in Newfoundland & Labrador

of treatment or care in a plan, pathway, algorithm, guideline, protocol or other 'inventory of actions;' ? the intervention had timeframes or criteria-based progression; and ? the intervention aimed to standardize care for a specific clinical problem, procedure or episode of healthcare in a specific population (2) Early Discharge (ED) Interventions initiated during the acute phase of an illness or injury to facilitate transition of care back to the community as soon as the acute event is stabilized (3

2018 Newfoundland and Labrador Centre for Health Information

286. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

with stable COPD or patients who had stabilized after an episode of ECOPD, but in more recent times, a number of trials have explored the role of exercise/early pulmonary rehabilitation during an episode of ECOPD. 27, 28 Chest physiotherapy using airway clearance techniques (including breathing technique, vibration/percussion, and autogenic drainage) are used routinely in many patients hospitalized with ECOPD. A Cochrane review published in 2012 found evidence that airway clearance techniques may reduce

2019 Effective Health Care Program (AHRQ)

287. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

. -,NO. -,2019 Hollenberg et al. -,2019:-–- Heart Failure Hospitalization Pathway 9TABLE 4 Key Comorbid Conditions to Consider Comorbidity Management Relevant Guidelines/Pathways Cardiovascular Coronary artery disease/acute coronary syndrome Assess and treat ischemia, and consider revascularization. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Atrial ?brillation/ ?utter (...) chain; ARB¼ angiotensin receptor blockers; ATTR¼ amyloid transthyretin; GDMT¼ guideline-directed medical therapy; HF¼ heart failure; HFrEF¼ heart failure with reduced ejection fraction; HTN¼ hypertension; RAAS¼ renin-angiotensin-aldosterone system; SGLT2¼ sodium-glucose cotransporter-2; STEMI¼ ST-segment elevation myocardial infarction. JACC VOL. -,NO. -,2019 Hollenberg et al. -,2019:-–- Heart Failure Hospitalization Pathway 11trial databases are continuous variables, while those from administrative

2019 American College of Cardiology

291. Management of Heart Failure (4th Edition)

: Outcome: ? Improvement in symptoms ? Reduce hospital readmissions for HF ? Reduction in Major Cardiovascular Disease Event Rate (myocardial infarction (MI), stroke, cardiovascular (CV) death) ? Reduction in all-cause mortality Type of Question - Involves: ? Therapy drug therapy, surgery, device therapy ? Harm - ? Worsening of symptoms and readmission rate ? Increase in cardiovascular event rate (MI, HF, CV death) ? Increase in bleeding risk and stroke rate ? Adverse effects due to pharmacotherapy (...) , orthopnoea, paroxysmal nocturnal dyspnoea, lung crepitations, jugular venous dilatation, hepatojugular reflux, congested hepatomegaly, gut congestion, ascites. From onset, evaluate to identify correctable/reversible lesions-arrhythmias, hypertension, myocardial ischaemia/infarction, valvular heart disease. - Diuretics, Continuous Infusion + Combination With Thiazides - Nitrates - Low Dose Dopamine - Dobutamine - Correct Hypoxia And Acidosis - Consider Invasive Ventilation - Refer To Tertiary Centres

2019 Ministry of Health, Malaysia

292. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy Full Text available with Trip Pro

exercise for desmosomal mutation carriers. Heart Rhythm . 2016 ; 13 : 199–207 | | | | | , x 255 Saberniak, J., Hasselberg, N.E., Borgquist, R. et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail . 2014 ; 16 : 1337–1344 | | | , x 258 Ruwald, A.C., Marcus, F., Estes, N.A. 3rd et al. Association of competitive and recreational sport participation with cardiac events (...) hypertrophy, whereas troponin I variants may cause a restrictive phenotype in which the dominant clinical presentation is atrial fibrillation. x 13 McKenna, W.J., Stewart, J.T., Nihoyannopoulos, P., McGinty, F., and Davies, M.J. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J . 1990 ; 63 : 287–290 | | | , x 14 Watkins, H., Ashrafian, H., and Redwood, C. Inherited cardiomyopathies. N Engl J Med . 2011 ; 364

2019 International Society for Heart and Lung Transplantation

296. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Full Text available with Trip Pro

of thrombosis. It is used in patients without verified vascular disease and to reduce the risk of vascular events in patients at high risk or those with a history of myocardial infarction or stroke. Aspirin irreversibly inhibits cyclooxygenase (COX)-1, resulting in reduced thromboxane A2 production, which subsequently decreases platelet aggregation and activation. Aspirin has a mild antiplatelet effect, acts within 15–30 minutes, and is rapidly metabolized into its nonactive metabolite. The lifespan (...) P2Y12 inhibitor that has a rapid onset of action with a short half-life of 3–6 minutes. It is used in acute coronary care for the prevention of periprocedural myocardial infarction or stent thrombosis, with patients being transitioned to an oral thienopyridine agent postprocedurally. Cangrelor can also be used as a “bridge” therapy option for patients receiving oral thienopyridines before surgery ( x 38 Angiolillo, D.J., Firstenberg, M.S., Price, M.J , and BRIDGE Investigators. Bridging antiplatelet

2019 Society of Interventional Radiology

297. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. Full Text available with Trip Pro

) ( x 13 Lane, D.A. and Lip, G.Y. Use of the CHADS-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation . 2012 ; 126 : 860–865 ) (13) . The acryonm represents underlying cardiovascular risk factors used to calculate the score: congestive hear failiure (C), hypertension (H), age (A), diabetes (D), stroke/transient ischemic attack (S), and vascular diseases (VASc) such as peripheral arterial disease, previous myocardial infarction (...) of thrombotic risk, especially when newly implanted ( x 18 Dangas, G.D., Weitz, J.I., Giustino, G., Makkar, R., and Mehran, R. Prosthetic heart valve thrombosis. J Am Coll Cardiol . 2016 ; 68 : 2670–2689 ) (18) . Coronary Artery Disease As discussed in part I of these guidelines, significant morbidity and potential for thromboembolic complications exist if such patients are mismanaged ( x 20 Windecker, S., Kolh, P., Alfonso, F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force

2019 Society of Interventional Radiology

298. Telehealth for Acute and Chronic Care Consultations

department; EMS = emergency medical services; KQ = Key Question; RR = risk ratio; STEMI = ST-elevation myocardial infarction; tPA = tissue plasminogen activator; Outpatient Telehealth Consultations • Clinical outcomes: Clinical outcomes were reported in just over one-quarter of the studies of telehealth consultations and in 7 of 11 clinical topics. In three topics, there is moderate strength of evidence of the benefits of telehealth (better healing in wound care, higher response to treatment

2019 Effective Health Care Program (AHRQ)

300. Treatment of Diabetes in Older Adults Full Text available with Trip Pro

the next 3 decades; as the population ages, the numbers of higher-risk minority groups increase, and people with diabetes live longer because of decreasing rates of cardiovascular deaths ( ). Moreover, older adults are susceptible to all of the usual complications of diabetes [reviewed in Refs. ( ) and ( )]. The prevalence rates of end-stage renal disease, loss of vision, myocardial infarction, stroke, peripheral vascular disease, and peripheral neuropathy are increased by the presence of diabetes (...) identified 23 randomized trials. For primary prevention, statins reduced the risk of coronary artery disease and myocardial infarction, but not all-cause or cardiovascular mortality or stroke. These effects were imprecise in patients with diabetes, but there was no significant interaction between diabetes status and the intervention effect. For secondary prevention, statins reduced all-cause mortality, cardiovascular mortality, coronary artery disease, myocardial infarction, and revascularization

2019 The Endocrine Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>